

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number	10/575,114
	Confirmation Number	9365
	Filing Date	April 10, 2006
	First Named Inventor	Shigeru IIDA
	Art Unit	Not Yet Assigned
	Examiner Name	Not Yet Assigned
	Attorney Docket Number	Q105982

U.S. PATENTS						
Examiner Initials*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1					

U.S. PATENT APPLICATION PUBLICATIONS						
Examiner Initials*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1					

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁵
	1							

NON-PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	T ⁵
	1	XP002355427 : SHINKAWA T ET AL: "The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody - dependent cellular cytotoxicity" Journal of Biological Chemistry, American Society For Biochemistry and Molecular Biology, Birmingham, US, Vol. 278, no. 5, January 31, 2003, pages 3466-3473	
	2	XP002442140 : SHIELDS ROBERT L ET AL: Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcγRIII and antibody - dependent cellular toxicity" JOURNAL OF BIOLOGICAL CHEMISTRY, American Society For Biochemistry and Molecular Biology, BIRMINGHAM, US. Vol. 277, No. 30 , July 26, 2002, pages 26733-26740	
	3	XP000941446 : NAKAMURA K ET AL: " CHIMERIC ANTI-GANGLIOSIDE GM2 ANTIBODY WITH ANTITUMOR ACTIVITY" CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, Vol. 54, No. 6 March 15, 1994, pages 1511-1516	
	4	XP002944543 : NAKAMURA KAZUYASU ET AL: " Apoptosis induction of the human lung cancer cell line in multicellular heterospheroids with humanized antiganglioside GM2 monoclonal antibody" CANCER RESEARCH, Vol. 59, No. 20, October 15, 1999, pages 5323-5330	

EXAMINER SIGNATURE			
Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 4 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 5 Applicant is to place a check mark here if English language translation is attached.